Johnson Investment Counsel Inc. Has $668,000 Stake in Sanofi (NASDAQ:SNY)

Johnson Investment Counsel Inc. decreased its stake in shares of Sanofi (NASDAQ:SNY) by 4.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 13,846 shares of the company’s stock after selling 701 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Sanofi were worth $668,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Sanofi by 31.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock worth $8,040,000 after purchasing an additional 33,105 shares in the last quarter. Arkadios Wealth Advisors lifted its holdings in shares of Sanofi by 19.0% in the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after purchasing an additional 751 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Sanofi by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after purchasing an additional 16,780 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Finally, Kentucky Trust Co bought a new position in shares of Sanofi in the 4th quarter worth $436,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Sanofi has an average rating of “Buy” and an average target price of $60.00.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $57.69 on Thursday. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock’s fifty day simple moving average is $53.27 and its two-hundred day simple moving average is $52.81. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12. The stock has a market cap of $146.41 billion, a PE ratio of 23.17, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.